The clinicopathologic spectrum and management of nonalcoholic fatty liver disease

Advances in Anatomic Pathology

Volumn 9, Issue 1, 2002, Pages 37-51

  Contos, Melissa J ^a   Sanyal, Arun J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Fatty liver; Insulin resistance; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity

Indexed keywords

ADOLESCENT; ADULT; AGED; CHILD; FATTY LIVER; HUMAN; LIVER; LIVER TRANSPLANTATION; PATHOLOGY; PRESCHOOL CHILD; REVIEW;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FATTY LIVER; HUMAN; LIVER; LIVER TRANSPLANTATION; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0036134022     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200201000-00005     Document Type: Article

References (105)

1. Zelman S. The liver in obesity. Arch Intern Med 1958;90:141-56.
2. Catlin R. Liver dysfunction after intestinal bypass. JAMA 1963;1693-4.
3. Nasrallah SM, Wills CE, Jr, Galambos JT. Liver injury following jejunoileal bypass. Are there markers? Ann Surg 1980;192:726-9. (Pubitemid 11210693)
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8. (Pubitemid 10057164)
5. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80. (Pubitemid 20075105)
6. Brunt EM, Janney CG, DiBisceglie AM, Neuschwander Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 2000;94:2467-74.
7. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5. (Pubitemid 29528333)
8. Lonardo A, Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution [In Process Citation]. J Gastroenterol Hepatol 2000;15:775-82. (Pubitemid 30615062)
9. James OF, Day CP. Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance [see comments]. J Hepatol 1998;29:495-501. (Pubitemid 28396672)
10. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-9.
11. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;11:74-80.
12. Ground KEV. Prevalence of fatty liver in healthy adults accidentally killed. Aviat Space Environ Med 1984;55:59-61.
13. Marcos A, Fisher RA, Ham JM, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000;69:2410-5. (Pubitemid 30409013)
14. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995;127:700-4.
15. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991 [see comments]. JAMA 1994;272:205-11. (Pubitemid 24209082)
16. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47. (Pubitemid 28036587)
17. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000;32:3-10. (Pubitemid 30432359)
18. Caprio S, Bronson M, Sherwin RS, Rife F, Tamborlane WV. Coexistence of severe insulin resistance and hyperinsulinaemia in preadolescent obese children. Diabetologia 1996;39:1489-97. (Pubitemid 26397355)
19. Chen W, Yu Z, Li Y. The relationship between nonalcoholic fatty liver and insulin resistance with abnormal glucose metabolism [in Chinese]. Zhongua Gan Zang Bing Za Zhi 2000;8:76-7.
20. Chen W, Srinivasan SR, Elkasabany A, Berenson GS. Cardiovascular risk factors clustering features of insulin resistance syndrome (Syndrome X) in a biracial (Black-White) population of children, adolescents, and young adults: the Bogalusa Heart Study. Am J Epidemiol 1999;150:667-74. (Pubitemid 29463192)
21. Luyckx FH, Lefebvre PJ, Scheen AJ. Nonalcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000;26:98-106. (Pubitemid 30307580)
22. Reaven G. Syndrome X: 10 years after. Drugs 1999;58(Suppl 1):19-20, 75-82 (discussion).
23. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594-8. (Pubitemid 19164370)
24. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650-4. (Pubitemid 17095826)
25. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; nonalcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992;27:521-8.
26. Bacon BR, Farahvash MJ, Janney CG, Neuschwander Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity [see comments]. Gastroenterology 1994;107:1103-9. (Pubitemid 24294573)
27. Diehl AM, Goodman Z, Ishak KG. Alcoholic liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-62.
28. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinicopathologic comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-9. (Pubitemid 26064854)
29. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2000;120:1183-92.
30. Ahmed A, Keeffe EB. Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia. Am J Gastroenterol 1998;93:2598-9. (Pubitemid 29018585)
31. Ursich MJ, Fukui RT, Galvao MS, et al. Insulin resistance in limb and trunk partial lipodystrophy (type 2 Kobberling-Dunnigan syndrome). Metabolism 1997;46:159-63. (Pubitemid 27078760)
32. Acosta BS, Grimsley EW. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South Med J 1999;92:421-3. (Pubitemid 29197499)
33. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going? Dig Dis 1999;17:80-9. (Pubitemid 29463095)
34. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, de Moura MC. Nonalcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999;18:353-8. (Pubitemid 30032243)
35. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity [see comments]. J Clin Endocrinol Metab 1999;84:1513-7. (Pubitemid 30644245)
36. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
37. Arslanian SA, Kalhan SC. Correlations between fatty acid and glucose metabolism. Potential explanation of insulin resistance of puberty. Diabetes 1994;43:908-14. (Pubitemid 24196424)
38. Rigalleau V, De Tinguy E, Iron A, Aubertin J, Gin H. Lipid-carbohydrate interactions in postabsorptive noninsulin-dependent diabetic patients. Ann Nutr Metab 1997;41:108-17. (Pubitemid 27356827)
39. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects [published erratum appears in Diabetes 1996;45:1285]. Diabetes 1996;45:659-66. (Pubitemid 26140551)
40. Ferrannini E, Barrett EJ, Bevilaqua S, DeFronzo RA. Effects of free fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-47. (Pubitemid 14229053)
41. Marks DB, Marks AD, Smith CM. Formation and degradation of glycogen. In: Basic medical biochemistry. Baltimore: Williams & Wilkins, 1996:407-22.
42. Marks DB, Marks AD, Smith CM. Glucose metabolism in the liver: glycolysis and gluconeogenesis. In: Basic medical biochemistry. Baltimore: Williams & Wilkins, 1996;423-36.
43. Karjalainen L, Pihlajamaki J, Karhapaa P, Laakso M. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Arterioscler Thromb Vasc Biol 1998;18:1548-53. (Pubitemid 28465405)
44. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus. Lancet 1963;1:785-9.
45. Ogatta H, Akagi K, Nagamatsu A, Suzuki N, Nomiyama K, Fujishima M. Fatty liver in a case with heterozygous familial hypobetalipoproteinemia. Am J Gastroenterol 1997;92:339-42. (Pubitemid 27076490)
46. Shah SS, Desai HG. Apolipoprotein deficiency and chronic liver disease. J Assoc Physicians India 2001;49:274-8.
47. Day CP, James OF. Steatohepatitis: a tale of two "hits" [Editorial]. Gastroenterology 1998;114:842-5.
48. Berson A, De Beco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114:764-74. (Pubitemid 28160411)
49. Vendemiale G, Grattagliano I, Altomare E. An update on the role of free radicals and antioxidant defense in human disease. Int J Clin Lab Res 1999;29:49-55. (Pubitemid 29405190)
50. Weltman MD, Farrell GC, Hall P, Ingelman Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27:128-33. (Pubitemid 28041545)
51. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-75. (Pubitemid 30217691)
52. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
53. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-8. (Pubitemid 28093538)
54. Mosin VI, Yagoda AV. Synthesis of eicosanoids by circulating mononuclears in healthy people and in patients with liver cirrhosis. Hepatogastroenterology 1992;39:248-51.
55. Palmer CN, Gustafsson MC, Dobson H, von Wachenfeldt C, Wolf CR. Adaptive responses to fatty acids are mediated by the regulated expression of cytochromes P450. Biochem Soc Trans 1999;27:374-8. (Pubitemid 29412452)
56. Rolph CE, Roberts P, Taylor S. Phospholipase-induced modulation of rat liver mixed-function oxidase activity. Biochem Soc Trans 1999;27:371-4. (Pubitemid 29412451)
57. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103:253-9. (Pubitemid 29053143)
58. Clarke SD, Baillie R, Jump DB, Nakamura MT. Fatty acid regulation of gene expression. Its role in fuel partitioning and insulin resistance. Ann NY Acad Sci 1997;827:178-87.
59. Gries FA, Hubinger A. Lipid metabolism and insulin resistance - clinical aspects and pathobiochemistry [in German]. Wien Klin Wochenschr 1994;106:763-7.
60. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000;49:677-83. (Pubitemid 30339979)
61. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J Hepatol 1999;31:430-4.
62. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999;15:367-73. (Pubitemid 30233061)
63. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Gastrointestinal disturbances with obesity. Scand J Gastroenterol Suppl 1993;200:53-8. (Pubitemid 24093225)
64. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of gallstone disease in a general population of Okinawa, Japan [see comments]. Am J Epidemiol 1988;128:598-605.
65. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-9.
66. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650-4. (Pubitemid 17095826)
67. Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 1997;25:538-40. (Pubitemid 27528154)
68. da Silva PM, Eliseu T, Costa MM, Bastos H, Nobre FL. Nonalcoholic steatohepatitis [in Portugese]. Acta Med Port 1995;8:323-7.
69. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Nonalcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol 1999;31:421-9. (Pubitemid 29408723)
70. Younossi Z. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30:847-50. (Pubitemid 29458269)
71. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
72. Brunt EM. Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity [Editorial; see comment]. Liver 1999;19:263-4. (Pubitemid 29359088)
73. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathologic severity. Gastroenterology 1999;116:1413-9. (Pubitemid 29258890)
74. Contos MJ, Sterling RK, Luketic V-A, et al. Syndrome X causes nonalcoholic fatty liver disease (NAFLD) in patients with hepatitis C (HCV) and increases the risk of cirrhosis [Abstract]. Am J Gastroenterol 2001;96:S119.
75. Tazawa J, Irie T, French SW. Mallory body formation runs parallel to g-glutamyl transferase induction in hepatocytes of griseofulvin fed mice. Hepatology 1983;3:989-1001. (Pubitemid 14247641)
76. Banner BF, Savas L, Zivny J, Tortorelli K, Bonkovsky HL. Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. Am J Clin Pathol 2000;114:860-6. (Pubitemid 33051885)
77. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9. (Pubitemid 29109578)
78. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-92.
79. Contos MJ, Cales W, Luketic VA, et al. Development of nonalcoholic fatty liver disease after liver transplant for cryptogenic cirrhosis. Liver Transpl 2001;7:363-73. (Pubitemid 32331542)
80. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998;11:560-5. (Pubitemid 28280720)
81. Fleiss JL. The measurement of interrater agreement. In: Statistical methods for rates and proportions. New York: Wiley, 1981:212-36.
82. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-6. (Pubitemid 28112021)
83. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 1970;282:829-34.
84. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-22. (Pubitemid 29173621)
85. Czaja AJ. Recurrence of nonalcoholic steatohepatitis after liver transplantation [Editorial]. Liver Transpl Surg 1997;3:185-6. (Pubitemid 27114034)
86. Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 1997;3:174-6. (Pubitemid 27114030)
87. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802-5. (Pubitemid 27014542)
88. Lewis KO, Paton A. Tools of alcohol detection. BMJ 1981;283:1531-2.
89. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983;139:43-50. (Pubitemid 13164807)
90. Gore RM. Diffuse liver disease. In: Gore RM, Levine MS, Laufer I, eds. Textbook of gastrointestinal radiology. Philadelphia: W.B. Saunders, 1994:1968-2017.
91. Vajro P, Fontanella A, Perna C. Persistent hyperaminotransferasemia resolving after Wright reduction in obese children. J Pediatr 1994;125:239-42.
92. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 1980;137:727-9. (Pubitemid 11203707)
93. Kreft B, Tanimoto A, Baba Y, et al. Diagnosis of fatty liver with MR imaging. J Magn Reson Imaging 1983;2:466-71.
94. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-8. (Pubitemid 19231304)
95. Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities [In Process Citation]. Am J Gastroenterol 2000;95:3206-10.
96. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol induced steatohepatitis: a pilot study. Hepatology 1996;23:74-80.
97. McCullough AJ, Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic liver disease [Editorial; see comment]. Hepatology 1999;29:1328-30. (Pubitemid 29168773)
98. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7. (Pubitemid 27357062)
99. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986;220:83-8. (Pubitemid 16041850)
100. Petrides AS, Matthews DE, Esser U. Effect of moderate exercise on insulin sensitivity and substrate metabolism during postexercise recovery in cirrhosis. Hepatology 1997;26:972-9. (Pubitemid 27413666)
101. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator activated receptors. Lancet 1999;354:141-8. (Pubitemid 29313157)
102. Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999;55:932-43. (Pubitemid 29304447)
103. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
104. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study [see comments]. J Pediatr 2000;136:734-8. (Pubitemid 30415645)
105. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [Letter; see comment]. J Hepatol 1999;31:384. (Pubitemid 29349772)